Intrabodies as neuroprotective therapeutics

Area of Science:

• Neuroscience
• Biotechnology
• Immunology

Background:

• Neurodegenerative diseases often stem from intracellular protein misfolding.
• Antibodies can be engineered to target these misfolded proteins or downstream pathological events.
• Intracellular antibody fragments (intrabodies and nanobodies) represent an emerging therapeutic strategy.

Purpose of the Study:

• To review the emerging field of engineering intracellular antibody fragments for neurodegeneration.
• To highlight the potential of intrabodies and nanobodies as therapeutic agents.
• To discuss applications in diseases like Huntington's and Parkinson's disease.

Main Methods:

• Review of existing literature on intrabodies and nanobodies in neurodegeneration.
• Identification of single-chain variable fragments (scFv) and single-domain nanobodies against specific targets.
• Analysis of data for rational design of bifunctional constructs and target validation.

Main Results:

• Huntington's disease serves as a key proof-of-concept model for this therapeutic approach.
• Intrabodies targeting alpha-synuclein for Parkinson's disease are also under investigation.
• Recombinant antibody technology is a powerful tool with significant potential for neurological diseases.

Conclusions:

• Engineered intracellular antibody fragments offer a promising therapeutic avenue for neurodegenerative disorders.
• Early intervention in carriers of genetic neurodegenerative diseases may be feasible.
• This biotechnology holds significant potential for developing novel treatments for neurological conditions.